Skip to main content
. 2022 Apr 19;27(6):432–e452. doi: 10.1093/oncolo/oyab075

Table 2.

Radiographic outcomes.

Cohort 1 
(N = 7) Cohort 2 
(N = 29) Overall 
(N = 36)
Response at 4 months
Complete response, N (%) 0 (0%) 0 (0%) 0 (0%)
Partial response, N (%) 0 (0%) 8 (27.6%) 8 (22.2%)
Stable disease, N (%) 0 (0%) 3 (10.3%) 3 (8.3%)
Progressive disease, N (%) 4 (57.1%) 9 (31%) 13 (36.1%)
Not evaluable, N (%) 3 (42.9%) 9 (31%) 12 (33.3%)
Best response
Complete response, N (%) 0 (0%) 1 (3.4%) 1 (2.8%)
Partial response, N (%) 0 (0%) 13 (44.8%) 13 (36.1%)
Stable disease, N (%) 4 (57.1%) 6 (20.7%) 10 (27.8%)
Prog. disease, N (%) 2 (28.6%) 4 (13.8%) 6 (16.7%)
Not evaluable, N (%) 1 (14.3%) 5 (17.2%) 6 (16.7%)